Evidence map›Paper›PMID 39858509›Full record

ArticleBiomolecules2025

Lipopolymers as the Basis of Non-Viral Delivery of Therapeutic siRNA Nanoparticles in a Leukemia (MOLM-13) Model.

Panadda Yotsomnuk, Amarnath Praphakar Rajendran, Daniel Nisakar Meenakshi Sundaram, Luis Carlos Morales, Cezary Kucharski, Mohammad Nasrullah, Wanwisa Skolpap, Xiaoyan Jiang, Spencer B Gibson, Joseph Brandwein and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Panadda YotsomnukDepartment of Chemical and Materials Engineering, Faculty of Engineering, University of Alberta, Edmonton, AB T6G 1R1, Canada.
Amarnath Praphakar RajendranDepartment of Chemical and Materials Engineering, Faculty of Engineering, University of Alberta, Edmonton, AB T6G 1R1, Canada.
Daniel Nisakar Meenakshi SundaramDepartment of Chemical and Materials Engineering, Faculty of Engineering, University of Alberta, Edmonton, AB T6G 1R1, Canada.
Luis Carlos MoralesDepartment of Chemical and Materials Engineering, Faculty of Engineering, University of Alberta, Edmonton, AB T6G 1R1, Canada.ORCID 0000-0003-4194-2961
Cezary KucharskiDepartment of Chemical and Materials Engineering, Faculty of Engineering, University of Alberta, Edmonton, AB T6G 1R1, Canada.
Mohammad NasrullahDepartment of Chemical and Materials Engineering, Faculty of Engineering, University of Alberta, Edmonton, AB T6G 1R1, Canada.ORCID 0000-0003-1346-355X
Wanwisa SkolpapDepartment of Chemical Engineering, Faculty of Engineering, Thammasat University, Pathumthani 12120, Thailand.ORCID 0000-0001-7017-1823
Xiaoyan JiangDepartment of Medical Genetics, Terry Fox Laboratory, British Columbia Cancer Research Institute, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.ORCID 0000-0002-8974-7340
Spencer B GibsonDepartment of Oncology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB T6G 1Z2, Canada.
Joseph BrandweinDivision of Hematology, Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB T6G 2B7, Canada.
Hasan UludağDepartment of Chemical and Materials Engineering, Faculty of Engineering, University of Alberta, Edmonton, AB T6G 1R1, Canada.ORCID 0000-0002-1118-4170

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small interfering RNA (siRNA) therapy in acute myeloid leukemia (AML) is a promising strategy as the siRNA molecule can specifically target proteins involved in abnormal cell proliferation. The development of a clinically applicable method for delivering siRNA molecules is imperative due to the challenges involved in effectively delivering the siRNA into cells. We investigated the delivery of siRNA to AML MOLM-13 cells with the use of two lipid-substituted polyethyleneimines (PEIs), a commercially available reagent (Prime-Fect) and a recently reported reagent with improved lipid substitution (PEI1.2k-PHPA-Lin9). The siRNAs utilized in this study were targeting the oncogenes FLT3 and KMT2A::MLLT3. Both lipopolymers gave similar-size siRNA complexes (210-220 nm) with positive

Indexed as

Leukemia, Myeloid, AcuteNanoparticlesPolymersRNA, Small InterferingAnimalsCell Line, Tumorfms-Like Tyrosine Kinase 3Gene SilencingHistone-Lysine N-MethyltransferaseHumansLipidsMiceMyeloid-Lymphoid Leukemia ProteinPolyethyleneimineFLT3 protein, humanfms-Like Tyrosine Kinase 3Histone-Lysine N-MethyltransferaseKMT2A protein, humanLipidsMyeloid-Lymphoid Leukemia ProteinPolyethyleneiminePolymersRNA, Small InterferingFLT3KMT2A::MLLT3lipopolymersMOLM-13nanoparticlesiRNA polyplexsiRNA therapy

Identifiers

PMID39858509
PMCPMC11763671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.